After the sale, Mr. Orsinger will stay with the company with a reduced base salary of $700,000 and the opportunity for bonuses. Johnson & Johnson agreed to purchase Synthes for $21.3 billion in April.
Related Articles on Orthopedic Device Companies:
Medtronic Launches T2 Altitude Expandable Corpectomy Device
ArthroCare to Settle Private Securities Class Action Suit
Bacterin Signs Distribution Agreement With Jeil for LeForte System
Synthes CEO to Make $52M in Johnson & Johnson Acquisition
Michel Orsinger, CEO of Synthes, recently received $52 million as a result of Johnson & Johnson’s acquisition of the company, if the deal closes sometime over the next two years, according to a Philadelphia Inquirer report.
Healthcare at a crossroads: Using concierge medicine to strengthen revenue, retention + patient satisfaction
Recommended Live Webinar on Mar 5, 2026 10:00 AM - 11:00 AM CST